

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC FOR
THE H SHARE FULL CIRCULATION
APPLICATION OF THE COMPANY**

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

Reference is made to the announcement (the “**Announcement**”) of the Company dated September 13, 2024 in relation to the application to the CSRC (the “**CSRC Filing**”) for the H Share Full Circulation by the Company. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on December 18, 2024, the CSRC issued a filing notice to the Company (the “**Filing Notice**”) in respect of the H Share Full Circulation. According to the Filing Notice, the CSRC Filing in relation to the H Share Full Circulation, in respect of the conversion of 173,641,645 Unlisted Shares held by 25 shareholders of the Company into 173,641,645 H shares has been completed. Upon completion of such conversion and listing approval granted by the Stock Exchange, such 173,641,645 H Shares will be listed and traded on the Main Board of the Stock Exchange. The Filing Notice will be valid for 12 months from the date of approval by the CSRC, being December 18, 2024. Please refer to the Announcement for details of the names of shareholders and number of Unlisted Shares for conversion under the H Share Full Circulation plan.

As at the date of this announcement, the details of the implementation plan of the H Share Full Circulation have not been finalized. The Company will make further announcement(s) on the progress of the H Share Full Circulation in compliance with the requirements under the Listing Rules and/or the Inside Information Provisions as and when appropriate.

The H Share Full Circulation is subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong
December 19, 2024

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.